# EDGAR Filing Document

**Accession Number:** 0001847367
**File Stem:** 0000000000-25-007198
**Filing Date:** 2025-7
**Character Count:** 2360
**Document Hash:** 1a7638e84ebf52c2064118a7093397cd
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-007198.hdr.sgml**: 20250917

**ACCESSION NUMBER**: 0000000000-25-007198

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250709

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ALUMIS INC.
- **CENTRAL INDEX KEY:** 0001847367
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 333-288510

**BUSINESS ADDRESS:**
- **STREET 1:** 280 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080
- **BUSINESS PHONE:** 650-231-6625

**MAIL ADDRESS:**
- **STREET 1:** 280 EAST GRAND AVENUE
- **CITY:** SOUTH SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94080

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ESKER THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20230427

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** FL2021-001, Inc.
- **DATE OF NAME CHANGE:** 20210222
**PUBLIC REFERENCE ACCESSION NUMBER**: 0001104659-25-065745

## Text-Extract

```

                                                           July 9, 2025

Martin Babler
President and Chief Executive Officer
Alumis Inc.
280 East Grand Avenue
South San Francisco, California 94080

       Re: Alumis Inc.
           Registration Statement on Form S-3
           Filed July 3, 2025
           File No. 333-288510
Dear Martin Babler:

       This is to advise you that we have not reviewed and will not review your
registration
statement.

        Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

       Please contact Chris Edwards at 202-551-6761 with any questions.

                                                           Sincerely,

                                                           Division of
Corporation Finance
                                                           Office of Life
Sciences
cc:   Chadwick L. Mills

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._